Use of prostaglandin E1, E2 or analogs to prevent renal failure induced by medical tests that utilize contrast media agents

US5807895A · kind A · utility

Assignee

• Schwarz Pharma Ltd. · DE

Inventors

• Henry T. Stratton · Glendale, US
• Tammy Antonucci · Mequon, US
• Erwin Schollmayer · Leverkusen, DE

Key dates

• Filing date: Nov 28, 1995
• Grant date: Sep 15, 1998
• Expiry date: Nov 28, 2015

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/5575
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method of preventing renal failure or dysfunction caused by medical tests which utilize contrast media by administering, preferably by intravenous infusion or injection, a prostaglandin selected from PGE.sub.1, PGE.sub.2, PGI.sub.2 or an analog or pharmaceutically acceptable salt thereof and preferably in a form of a complex with .alpha.-cyclodextrin, to a patient at risk, for example, a diabetic.